13Sep 2023
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma

Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma

A new study reveals that the experimental drug, Mezigdomide, in combination with dexamethasone, holds significant potential in treating relapsed and refractory multiple myeloma. In a phase 1-2 clinical trial, Mezigdomide demonstrated potent antiproliferative effects, even in cases resistant to existing treatments. Phase 1 identified a safe dose, 1.0 mg of Mezigdomide, to be taken once daily with dexamethasone in a 28-day cycle. In phase 2, 101 patients with triple-class-refractory myeloma participated, showing an overall response rate of 41%, with a median duration of response at 7.6 months. While common adverse effects included reversible neutropenia and infections, no unexpected toxicities emerged. This all-oral therapy offers hope for patients with limited treatment options for this incurable disease.

  • #oncology

Like

Save

Share